According to Zen Score, the 3 best pharma stocks to buy right now are:
1. Neurocrine Biosciences (NASDAQ:NBIX)
Neurocrine Biosciences (NASDAQ:NBIX) is the top pharmaceutical stock with a Zen Score of 64, which is 39 points higher than the pharmaceutical industry average of 25. It passed 21 out of 33 due diligence checks and has strong fundamentals. Neurocrine Biosciences has seen its stock return 32.39% over the past year, overperforming other pharmaceutical stocks by 39 percentage points.
Neurocrine Biosciences has an average 1 year
price target of $144.65, an upside of 6.37% from Neurocrine Biosciences's current stock price of $135.99.
Neurocrine Biosciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 17 analysts covering Neurocrine Biosciences, 47.06% have issued a Strong Buy rating, 23.53% have issued a Buy, 29.41% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Pacira Biosciences (NASDAQ:PCRX)
Pacira Biosciences (NASDAQ:PCRX) is the second best pharmaceutical stock with a Zen Score of 58, which is 33 points higher than the pharmaceutical industry average of 25. It passed 18 out of 33 due diligence checks and has strong fundamentals. Pacira Biosciences has seen its stock lose -40.25% over the past year, underperforming other pharmaceutical stocks by -33 percentage points.
Pacira Biosciences has an average 1 year
price target of $47.57, an upside of 80.67% from Pacira Biosciences's current stock price of $26.33.
Pacira Biosciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Pacira Biosciences, 28.57% have issued a Strong Buy rating, 71.43% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Siga Technologies (NASDAQ:SIGA)
Siga Technologies (NASDAQ:SIGA) is the third best pharmaceutical stock with a Zen Score of 58, which is 33 points higher than the pharmaceutical industry average of 25. It passed 21 out of 38 due diligence checks and has strong fundamentals. Siga Technologies has seen its stock return 60.11% over the past year, overperforming other pharmaceutical stocks by 67 percentage points.